Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | CALML3 | P27482 | 1/20 | 0.46 |
| ▸ | SDHA | P31040 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 10/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477911 | 0.90 | MAOA (0.57) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6478267 | 0.89 | F10 (0.48) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5294528 | 0.88 | MAOA (0.49) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5278690 | 0.88 | MAOA (0.49) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6233915 | 0.87 | MAOA (0.48) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6486390 | 0.86 | MAOA (0.44) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5325395 | 0.86 | MAOA (0.49) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6485388 | 0.85 | F10 (0.44) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5329301 | 0.85 | MAOA (0.49) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6210106 | 0.85 | MAOA (0.43) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6875784-B2 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040127530-A1 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127530-A1 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | OXA1L, CYP1B1, MT-CO1 | MAOA 743/4885MAOB 739/4885LMNA 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.